Free Trial

Galmed Pharmaceuticals (GLMD) Competitors

Galmed Pharmaceuticals logo
$3.34
-0.16 (-4.57%)
(As of 10/31/2024 ET)

GLMD vs. ANL, CLRB, ALXO, VRCA, SPRO, CTXR, RAPT, ZIVO, OMGA, and ONCO

Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Adlai Nortye (ANL), Cellectar Biosciences (CLRB), ALX Oncology (ALXO), Verrica Pharmaceuticals (VRCA), Spero Therapeutics (SPRO), Citius Pharmaceuticals (CTXR), RAPT Therapeutics (RAPT), ZIVO Bioscience (ZIVO), Omega Therapeutics (OMGA), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry.

Galmed Pharmaceuticals vs.

Adlai Nortye (NASDAQ:ANL) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Adlai Nortye presently has a consensus target price of $9.00, indicating a potential upside of 350.00%. Given Adlai Nortye's higher probable upside, research analysts plainly believe Adlai Nortye is more favorable than Galmed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adlai Nortye
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Galmed Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Adlai Nortye's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Adlai NortyeN/A N/A N/A
Galmed Pharmaceuticals N/A -27.06%-23.47%

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Galmed Pharmaceuticals received 435 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Adlai NortyeOutperform Votes
7
100.00%
Underperform Votes
No Votes
Galmed PharmaceuticalsOutperform Votes
442
63.69%
Underperform Votes
252
36.31%

Galmed Pharmaceuticals has lower revenue, but higher earnings than Adlai Nortye.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adlai Nortye$5M14.76-$104.87MN/AN/A
Galmed PharmaceuticalsN/AN/A-$6.91M-$2.40-1.39

In the previous week, Adlai Nortye and Adlai Nortye both had 2 articles in the media. Adlai Nortye's average media sentiment score of 1.58 beat Galmed Pharmaceuticals' score of 0.84 indicating that Adlai Nortye is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adlai Nortye
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Galmed Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Adlai Nortye beats Galmed Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLMD vs. The Competition

MetricGalmed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$16.85M$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio-0.1916.06131.9317.57
Price / SalesN/A258.281,440.1578.36
Price / CashN/A50.1639.0633.56
Price / Book0.105.674.744.57
Net Income-$6.91M$151.16M$115.43M$225.42M
7 Day Performance-17.12%-1.80%-0.86%-0.61%
1 Month Performance-51.31%5.92%3.61%1.50%
1 Year Performance-26.75%39.97%38.90%32.94%

Galmed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLMD
Galmed Pharmaceuticals
2.0045 of 5 stars
$3.34
-4.6%
N/A-20.0%$16.85MN/A-0.1920Short Interest ↓
News Coverage
ANL
Adlai Nortye
3.225 of 5 stars
$2.00
-2.9%
$9.00
+350.0%
-76.1%$73.80M$5M0.00127Positive News
High Trading Volume
CLRB
Cellectar Biosciences
2.8793 of 5 stars
$2.05
flat
$21.00
+924.4%
-14.6%$73.49MN/A-0.6710Short Interest ↓
ALXO
ALX Oncology
3.3654 of 5 stars
$1.40
-4.1%
$12.50
+792.9%
-79.9%$72.94MN/A-0.3840Positive News
VRCA
Verrica Pharmaceuticals
4.1951 of 5 stars
$1.68
+7.7%
$11.40
+578.6%
-54.4%$71.27M$13.91M-0.8940Short Interest ↑
SPRO
Spero Therapeutics
4.7378 of 5 stars
$1.31
+1.6%
$7.00
+434.4%
+25.2%$70.72M$105.43M3.9746News Coverage
Gap Down
High Trading Volume
CTXR
Citius Pharmaceuticals
3.217 of 5 stars
$0.39
+5.4%
$4.00
+924.6%
-46.0%$70.54MN/A-1.6320Positive News
RAPT
RAPT Therapeutics
4.0496 of 5 stars
$2.00
+3.6%
$18.17
+808.3%
-81.0%$69.81M$1.53M-0.6480
ZIVO
ZIVO Bioscience
N/A$19.95
flat
N/A+640.0%$69.63M$30,000.00-3.7910Positive News
OMGA
Omega Therapeutics
1.9655 of 5 stars
$1.24
-2.4%
$10.20
+722.6%
-14.2%$68.39M$3.09M-0.87120
ONCO
Onconetix
1.5267 of 5 stars
$3.04
-15.1%
N/AN/A$67.88M$1.46M0.0012Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:GLMD) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners